Eris Lifesciences Ltd To Discuss Joint Venture with Mj Biopharm Pvt Ltd Call Transcript

Dec 04, 2021 / 04:30AM GMT
Operator

Ladies and gentlemen, good day, and welcome to the conference call of Eris Lifesciences. (Operator Instructions) Please note that this conference is being recorded.

I now hand the conference over to Mr. V. Krishnakumar, Chief Operating Officer and Executive Director of the company. Thank you, and over to you, sir.

Krishnakumar Vaidyanathan - Eris Lifesciences Limited - Executive Director & COO

Good morning. I'm happy to share with you today that Eris has announced its entry into India's insulin and GLP-1 agonist market through Eris MJ Biopharm Limited, a special purpose joint venture between Eris and Mumbai-based MJ Biopharm Private Ltd. The insulin and GLP-1 market in India is presently worth INR 3,500 crores to INR 4,000 crores, and we expect that to double over the next 5 years. So we are talking of an addressable market of nearly INR 8,000 crores by the year 2025, '26.

Eris, one of India's leading players in the overall diabetes care segment, will now extend its product offering to insulin and GLP-1 agonist. The 70-30 joint venture,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot